“益生菌1号”治疗肠易激综合征的临床疗效研究.

Objective To investigate the efficacy of "probiotics No. 1" in the treatment of irritable bowel syndrome(IBS). A total of 300 patients with diarrhen type IRS (IBS-D) and constipation type IBS (IBS-C) who were diagnosed and trea ted in the hospital from July to December 2020 were randomly divided into test group with 154 cases (IBS C test subgroup 40 cases, IBS-D test subgroup 114 cases) and control group with 146 cases (IBS-C control subgroup 36 cases. IBS-D control subgroup 110 cases) respectively orally take "probiotics No. 1 and placebo for 2 weeks. The IRS severity questionnaire (IBS SSS) score and the Bristol classification (Bristol) classification score of the patients in each group were evaluated at 0,1,2 weeks of medication and 1 week of drug withdrawal. The IBS quality of life scale (IBS-QOL) score of each group - evaluated for 2 weeks, and the occur rence of adverse reactions during the medication was recorded. Results A total of 264 cases were completed, including 134 cases in the test group (37 cases in the IBS-C test subgroup. 97 cases in the IBS-D test subgroup) 130 cases in the control group (35 cases in the IBS-C control subgroup, and 95 cases in the IBS-D control subgroup). IBS-SSS scores of patients in the test group. control group. IBS-D test subgroup and IBS-D control subgroup at after 1 and 2 weeks of medication, and the stool Bristol scores of patients in the IBS-D test subgroup and control subgroup at after 1 and 2 weeks of medication were significantly lower than those before medication, and the decline in the test group and IBS-D test subgroup were more significant than those of the control group and IBS D control subgroup, and the differences were statistically significant (P<0,05), The IBS-SSS scores of patients in the IBS-C test subgroup was only significantly lower after 2 weeks of medication than that before medication, and the difference was statistically significant (P<0, 05). The response rate of IBS-SSS score in the test group was significantly higher than that in the control group, and the difference was statistically significant (P<0, 05), One week after the drug was stopped, IBS SSS score of the control group and IBS-D control subgroups had a significant increase, IBS-C control subgroups had a significant decrease in stool Bristol classification scores compared with those at after 2 weeks of medication, and the differences were statistically significant (P<0.05). The test group and IBS-D, IBS-C test subgroups had no significant changes compared with the previous ones. After taking the drug for 2 weeks, the IBS QOL scores of the patients in test group.control group, IBS-D test subgroup and IBS-D control subgroup were significantly lower than those before medication and the test group and IBS-D test subgroup decreased compared with the control group and IBS-D control subgroup were more obvious, and the differences were statistically significant (P<0, 05). The changes in IBS QOL scores before and after medication in the IBS-C test and control subgroups were statistically significant (P<0.05) and there were no differences between the groups. Conclusion Compared with placebo, taking "probiotics No. 1 for 2 weeks can improve the overall symptoms, stool characteristics and quality of life of IBS patients especially in IBS-D patients. It is worthy of climcal promotion. [ABSTRACT FROM AUTHOR]